Venous Thrombosis and Pulmonary Embolism

Inclusion Criteria

- Adult female and male patients with active cancer other than fully treated basal-cell or squamous-cell carcinoma of the skin (active cancer defined as the diagnosis or treatment of cancer in the previous < 6 months or recurrent or metastatic cancer)
- Patients that have been treated with standard of care anticoagulation (Low Molecular Weight Heparin / Vitamin K Antagonist) for treatment of DVT and/ or PE (index VTE event) and/ or prevention of recurrent DVT and PE for at least 4 weeks prior to inclusion in the study
- Patients for whom the decision was made to start rivaroxaban for treatment of DVT and/ or PE and/ or prevention of recurrent DVT and PE
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 
- Patients who are willing to participate in this study (signed informed consent) 
- Patients who are available for follow-up with a life expectancy >6 months

Exclusion Criteria

- The contra-indications according to the local marketing authorization must be considered
- Patients who developed an index VTE event despite chronic anticoagulant therapy
- Patients receiving apixaban, edoxaban or dabigatran or any investigational drug as the initial therapy for the index VTE event 
- Patients participating in an investigational program with interventions outside of routine clinical practice with exception of oncology investigational trials